Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page # w. t2 x9 _7 s4 C3 p; G% Y8 n$ T
5 r/ n. ?4 t$ \; v* N8 R# M3 D
9 @4 Q! r! k4 b) D' S9 D y
Sub-category:. q: T/ F2 E/ C! }8 [2 T E; }" C
Molecular Targets
3 E5 {% R# I$ l0 v& K3 j" F, h& G. ?" Y9 G5 l% R
; [2 C* ?) Z$ F3 K. }+ r; W" Q
Category:; b: C, L' \; I! v& I$ a, _' z! F$ e
Tumor Biology ( `$ c: | y+ r" W6 k
" e5 p }4 i+ j4 d/ T
: O9 _# J" ]0 V8 V5 [/ @Meeting:+ n7 ?; s& O9 Q6 V: @5 u
2011 ASCO Annual Meeting
( M' n0 I: C% N2 x" E$ U2 X* H# T! P1 t6 I
' h, G# Z+ x2 MSession Type and Session Title:# z" ^, T( O( ~& \
Poster Discussion Session, Tumor Biology , }+ S- }7 |2 z( }8 N0 N; }' @
f, _7 n" V6 E6 V* i& q& y
- ` O9 N8 ^0 C1 H3 R1 E0 X
Abstract No:! c: `# ~; g8 R8 ^
10517 4 G! [6 u0 m! t+ j; g7 P
6 ^& U. y8 b" k' D
& s6 ]# w! q* i, J8 `# P/ j# Q
Citation:# l2 H7 K2 z n9 X8 c$ f H
J Clin Oncol 29: 2011 (suppl; abstr 10517)
U% c) F3 _8 k. L/ n
! Y( H8 X/ D0 y7 [/ z, ~
, {% ~, n+ |! L7 M# F, j( fAuthor(s):6 E+ e, Y( g; Y4 t6 G- I" i$ M
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China " o1 h( Q$ @) x( u* X, \
0 a+ U' H( _3 k# t
0 }& t# q& D2 M' S
+ ]; E1 x r& i s; Y$ A7 c
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
/ E. X5 D1 T; e) V- J4 ?' Q" C; r* T+ d, Q4 i% @7 c( n
Abstract Disclosures$ U2 ^: ^$ e: s
1 c/ Z1 Q9 ^: ]/ Q& f S) X# d
Abstract:6 d F) a' `( {* |* y# F' n
$ B S) w& X v, o5 X: C! v4 V3 k
1 m4 m9 p4 b+ c+ d& |Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.3 U6 `; `- t7 f9 \7 d
- l: M2 x. p$ p
3 l- O. h" A, M |
显身卡
